Cargando…
The first-in-class alkylating HDAC inhibitor EDO-S101 is highly synergistic with proteasome inhibition against multiple myeloma through activation of multiple pathways
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5549260/ https://www.ncbi.nlm.nih.gov/pubmed/28753594 http://dx.doi.org/10.1038/bcj.2017.69 |
| _version_ | 1783255942655115264 |
|---|---|
| author | Besse, L Kraus, M Besse, A Bader, J Silzle, T Mehrling, T Driessen, C |
| author_facet | Besse, L Kraus, M Besse, A Bader, J Silzle, T Mehrling, T Driessen, C |
| author_sort | Besse, L |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-5549260 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2017 |
| publisher | Nature Publishing Group |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-55492602017-08-11 The first-in-class alkylating HDAC inhibitor EDO-S101 is highly synergistic with proteasome inhibition against multiple myeloma through activation of multiple pathways Besse, L Kraus, M Besse, A Bader, J Silzle, T Mehrling, T Driessen, C Blood Cancer J Letter to the Editor Nature Publishing Group 2017-07 2017-07-28 /pmc/articles/PMC5549260/ /pubmed/28753594 http://dx.doi.org/10.1038/bcj.2017.69 Text en Copyright © 2017 The Author(s) http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
| spellingShingle | Letter to the Editor Besse, L Kraus, M Besse, A Bader, J Silzle, T Mehrling, T Driessen, C The first-in-class alkylating HDAC inhibitor EDO-S101 is highly synergistic with proteasome inhibition against multiple myeloma through activation of multiple pathways |
| title | The first-in-class alkylating HDAC inhibitor EDO-S101 is highly synergistic with proteasome inhibition against multiple myeloma through activation of multiple pathways |
| title_full | The first-in-class alkylating HDAC inhibitor EDO-S101 is highly synergistic with proteasome inhibition against multiple myeloma through activation of multiple pathways |
| title_fullStr | The first-in-class alkylating HDAC inhibitor EDO-S101 is highly synergistic with proteasome inhibition against multiple myeloma through activation of multiple pathways |
| title_full_unstemmed | The first-in-class alkylating HDAC inhibitor EDO-S101 is highly synergistic with proteasome inhibition against multiple myeloma through activation of multiple pathways |
| title_short | The first-in-class alkylating HDAC inhibitor EDO-S101 is highly synergistic with proteasome inhibition against multiple myeloma through activation of multiple pathways |
| title_sort | first-in-class alkylating hdac inhibitor edo-s101 is highly synergistic with proteasome inhibition against multiple myeloma through activation of multiple pathways |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5549260/ https://www.ncbi.nlm.nih.gov/pubmed/28753594 http://dx.doi.org/10.1038/bcj.2017.69 |
| work_keys_str_mv | AT bessel thefirstinclassalkylatinghdacinhibitoredos101ishighlysynergisticwithproteasomeinhibitionagainstmultiplemyelomathroughactivationofmultiplepathways AT krausm thefirstinclassalkylatinghdacinhibitoredos101ishighlysynergisticwithproteasomeinhibitionagainstmultiplemyelomathroughactivationofmultiplepathways AT bessea thefirstinclassalkylatinghdacinhibitoredos101ishighlysynergisticwithproteasomeinhibitionagainstmultiplemyelomathroughactivationofmultiplepathways AT baderj thefirstinclassalkylatinghdacinhibitoredos101ishighlysynergisticwithproteasomeinhibitionagainstmultiplemyelomathroughactivationofmultiplepathways AT silzlet thefirstinclassalkylatinghdacinhibitoredos101ishighlysynergisticwithproteasomeinhibitionagainstmultiplemyelomathroughactivationofmultiplepathways AT mehrlingt thefirstinclassalkylatinghdacinhibitoredos101ishighlysynergisticwithproteasomeinhibitionagainstmultiplemyelomathroughactivationofmultiplepathways AT driessenc thefirstinclassalkylatinghdacinhibitoredos101ishighlysynergisticwithproteasomeinhibitionagainstmultiplemyelomathroughactivationofmultiplepathways AT bessel firstinclassalkylatinghdacinhibitoredos101ishighlysynergisticwithproteasomeinhibitionagainstmultiplemyelomathroughactivationofmultiplepathways AT krausm firstinclassalkylatinghdacinhibitoredos101ishighlysynergisticwithproteasomeinhibitionagainstmultiplemyelomathroughactivationofmultiplepathways AT bessea firstinclassalkylatinghdacinhibitoredos101ishighlysynergisticwithproteasomeinhibitionagainstmultiplemyelomathroughactivationofmultiplepathways AT baderj firstinclassalkylatinghdacinhibitoredos101ishighlysynergisticwithproteasomeinhibitionagainstmultiplemyelomathroughactivationofmultiplepathways AT silzlet firstinclassalkylatinghdacinhibitoredos101ishighlysynergisticwithproteasomeinhibitionagainstmultiplemyelomathroughactivationofmultiplepathways AT mehrlingt firstinclassalkylatinghdacinhibitoredos101ishighlysynergisticwithproteasomeinhibitionagainstmultiplemyelomathroughactivationofmultiplepathways AT driessenc firstinclassalkylatinghdacinhibitoredos101ishighlysynergisticwithproteasomeinhibitionagainstmultiplemyelomathroughactivationofmultiplepathways |